scispace - formally typeset
Search or ask a question
Institution

Gdańsk Medical University

EducationGdańsk, Poland
About: Gdańsk Medical University is a education organization based out in Gdańsk, Poland. It is known for research contribution in the topics: Population & Cancer. The organization has 4893 authors who have published 11216 publications receiving 260523 citations.


Papers
More filters
Journal ArticleDOI
TL;DR: In recent years, development of sample-preparation techniques with significant advantages over conventional methods for the extraction of organic compounds from different samples became increasingly important as mentioned in this paper, and Coacervates emerged as promising environment-friendly alternatives for sample preparation.
Abstract: In recent years, development of sample-preparation techniques with significant advantages over conventional methods for the extraction of organic compounds from different samples became increasingly important. Coacervates emerged as promising environment-friendly alternatives for sample preparation. This review covers the basic theory of coacervates and summarizes recent applications (2010–15) of coacervates for preconcentration of organic compounds, metal ions and nanoparticles from various types of sample.

68 citations

Journal ArticleDOI
TL;DR: Treating future parents, as well as pregnant and lactating women with AD, the use of topical treatments including moisturizers, topical corticosteroids, tacrolimus, antiseptics andUltraviolet therapy may also be used.
Abstract: Atopic dermatitis (AD) is a common inflammatory skin disease that affects both children and adults, including a large number of adults of reproductive age. Several guidelines for the treatment of AD exist, yet specific recommendations for the treatment of pregnant or lactating women and for adults planning to have a child are often lacking. This position paper from the European Task force on Atopic Dermatitis (ETFAD) is based on up-to-date scientific literature on treating pregnant and lactating women as wells as adults with AD planning to have a child. It is based on the expert opinions of members of the ETFAD and on existing safety data on the proposed treatments, many of which are derived from patients with other inflammatory diseases or from transplantation medicine. For treating future parents, as well as pregnant and lactating women with AD, the use of topical treatments including moisturizers, topical corticosteroids, tacrolimus, antiseptics such as chlorhexidine, octenidine, potassium permanganate and sodium hypochlorite (bleach) is deemed to be safe. Ultraviolet (UV) therapy may also be used. Systemic treatment should be prescribed only after careful consideration. According to the opinion of the ETFAD, treatment should be restricted to systemic corticosteroids and cyclosporine A, and, in selected cases, azathioprine.

68 citations

Journal ArticleDOI
TL;DR: The results indicate that only selective amygdaloid nuclei or their subdivisions project to the piriform cortex, and substantial projections from several Amygdaloids nuclei converge in the medial aspect of the posterior Piriform cortex.
Abstract: Projections from the amygdala to the piriform cortex are proposed to provide a pathway via which the emotional system can modulate the processing of olfactory information as well as mediate the spread of seizure activity in epilepsy. To understand the details of the distribution and topography of these projections, we injected the anterograde tracer Phaseolus vulgaris-leucoagglutinin into different nuclear divisions of the amygdaloid complex in 101 rats and analyzed the distribution and density of projections in immunohistochemically processed preparations. The heaviest projections from the amygdala to the piriform cortex originated in the medial division of the lateral nucleus, the periamygdaloid and sulcal subfields of the periamygdaloid cortex, and the posterior cortical nucleus. The heaviest terminal labeling was observed in layers Ib and III of the medial aspect of the posterior piriform cortex. Lighter projections to the posterior piriform cortex originated in the dorsolateral division of the lateral nucleus, the magnocellular and parvicellular divisions of the basal and accessory basal nuclei, and the anterior cortical nucleus. The projections to the anterior piriform cortex were light and originated in the dorsolateral and medial divisions of the lateral nucleus, the magnocellular division of the basal and accessory basal nuclei, the anterior and posterior cortical nuclei, and the periamygdaloid subfield of the periamygdaloid cortex. The results indicate that only selective amygdaloid nuclei or their subdivisions project to the piriform cortex. In addition, substantial projections from several amygdaloid nuclei converge in the medial aspect of the posterior piriform cortex. Via these projections, the amygdaloid complex can modulate the processing of olfactory information in the piriform cortex. In pathologic conditions such as epilepsy, these connections might provide pathways for the spread of seizure activity from the amygdala to extra-amygdaloid regions. J. Comp. Neurol. 476:414–428, 2004. © 2004 Wiley-Liss, Inc.

68 citations

Journal ArticleDOI
TL;DR: It is confirmed that many advanced GIST patients benefit from SU therapy with OS > 1.5 year, and primary tumor KIT/PDGFRA genotype and SU-induced AH, as surrogate of its antiangiogenic activity are two independent factors influencing both PFS and OS.
Abstract: Gastrointestinal stromal tumors (GIST) mutational status is recognized factor related to the results of tyrosine kinase inhibitors therapy such as imatinib (IM) or sunitinib (SU). Arterial hypertension (AH) is common adverse event related to SU, reported as predictive factor in renal cell carcinoma. The aim of the study was to analyze the outcomes and factors predicting results of SU therapy in inoperable/metastatic CD117(+) GIST patients after IM failure. We identified 137 consecutive patients with advanced inoperable/metastatic GIST treated in one center with SU (2nd line treatment). Median follow-up time was 23 months. Additionally, in 39 patients there were analyzed selected constitutive single nucleotide polymorphisms (SNPs) of VEGFA and VEGFR2 genes. One year progression-free survival (PFS; calculated from the start of SU) rate was 42% and median PFS was 43 weeks. The estimated overall survival (OS, calculated both from start of SU or IM) was 74 weeks and 51 months, respectively. One-year PFS was 65% (median 74 weeks) in 55 patients with AH vs. 22% (median 17 weeks) in patients without AH. Patients with primary tumors carrying mutations in KIT exon 9 or wild-type had substantially better 1-year PFS (68% and 57%; median 65.5 and 50.5 weeks, respectively) than patients having tumors with KIT exon 11 or PDGFRA mutations (34% and 15%; median 36.8 and 9 weeks, respectively). We identified two independent factors with significant impact on PFS and OS in univariate and multivariate analysis: primary tumor genotype and presence of AH. The most common adverse events during therapy were: fatigue, AH, hypothyroidism, hand and foot syndrome, mucositis, skin reactions, dyspepsia, and diarrhea. Two deaths were assessed as related to tumor rupture caused by reaction to SU therapy. The presence of C-allele in rs833061 and the T-allele in rs3025039 polymorphism of VEGFA were associated with significantly higher risk of hypothyroidism (OR: 10.0 p = 0.041 and OR: 10.5; p = 0.015, respectively). We confirmed that many advanced GIST patients benefit from SU therapy with OS > 1.5 year. Primary tumor KIT/PDGFRA genotype and SU-induced AH, as surrogate of its antiangiogenic activity are two independent factors influencing both PFS and OS. The preliminary data of this study were presented during Annual Meeting of American Society of Clinical Oncology, 4-8 June 2011 and Connective Tissue Oncology Society Meeting, 26-28 October 2011 in Chicago, IL.

68 citations

Journal ArticleDOI
TL;DR: The inflammaging concept was introduced in 2000 by Prof. Franceschi as discussed by the authors, which was an evolutionary or rather a revolutionary conceptualization of the immune changes in response to a lifelong stress.
Abstract: The inflammaging concept was introduced in 2000 by Prof. Franceschi. This was an evolutionary or rather a revolutionary conceptualization of the immune changes in response to a lifelong stress. This conceptualization permitted to consider the lifelong proinflammatory process as an adaptation which could eventually lead to either beneficial or detrimental consequences. This dichotomy is influenced by both the genetics and the environment. Depending on which way prevails in an individual, the outcome may be healthy longevity or pathological aging burdened with aging-related diseases. The concept of inflammaging has also revealed the complex, systemic nature of aging. Thus, this conceptualization opens the way to consider age-related processes in their complexity, meaning that not only the process but also all counter-processes should be considered. It has also opened the way to add new concepts to the original one, leading to better understanding of the nature of inflammaging and of aging itself. Finally, it showed the way towards potential multimodal interventions involving a holistic approach to optimize the aging process towards a healthy longevity.

68 citations


Authors

Showing all 4927 results

NameH-indexPapersCitations
Magdi H. Yacoub109126752431
Virend K. Somers10661554203
Felix Mitelman9557835416
Andrzej Slominski9146927900
Nils Mandahl8642725006
Fredrik Mertens8440628705
Enriqueta Felip8362253364
Pieter E. Postmus8138424039
Wilhelm Kriz7322219335
Godefridus J. Peters7352328315
Jacek Jassem7360235976
Piotr Rutkowski7256342218
Thomas Frodl7025816469
Eric J. Velazquez7039627539
Argye E. Hillis6839822230
Network Information
Related Institutions (5)
Polish Academy of Sciences
102.1K papers, 2M citations

88% related

University of Düsseldorf
49.1K papers, 1.9M citations

87% related

Hannover Medical School
27.4K papers, 1M citations

87% related

Peking Union Medical College
61.8K papers, 1.1M citations

86% related

University of Verona
29.9K papers, 968.9K citations

86% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
202317
202264
20211,092
20201,004
2019863
2018802